London Stock Exchange welcomes Fusion Antibodies plc to AIM

London Stock Exchange today welcomes Fusion Antibodies Plc (‘Fusion’ or the ‘Company’), a contract research organisation providing a range of engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, to celebrate the listing of the Company's public shares onto AIM, under the ticker "FAB".

Fusion is a Belfast based, revenue generating and profitable CRO providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The Company provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRxTM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced over 250 antibodies and successfully completed over 100 humanisation projects for its international, blue-chip client base, which includes eight of the top 10 global pharmaceutical companies by revenue.

The Company has successfully raised £5.5 million (before expenses) through a placing of new Ordinary Shares, to fund the expansion of its existing laboratory space, increase its sales and marketing efforts, for the development of the new service lines, as well as providing additional working capital. In addition, £1.1 million worth of shares were placed with new investors on behalf of selling shareholders. On Admission, the Company will have a market capitalisation of approximately £18.1m.

Dr Paul Kerr, CEO of Fusion, commented: “We are very pleased with the level of interest generated from new institutional investors in support of our admission to trading on AIM. We have established Fusion as a multi-service CRO for antibody engineering & humanisation, and cell line development for the world’s largest developers of antibody-based therapeutics drugs and diagnostics companies. The move to AIM and the additional funding will allow us to continue this growth trajectory by expanding our capacity and developing our offering of new, high value, market differentiating products.”

To find out more about Fusion visit: